Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceu
(NQ:
RARE
)
56.96
-0.83 (-1.44%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ultragenyx Pharmaceu
< Previous
1
2
3
4
5
Next >
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
May 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
May 16, 2022
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from...
Via
Benzinga
Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know
May 10, 2022
Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9%...
Via
Benzinga
Earnings Scheduled For February 10, 2022
February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.
Via
Benzinga
Earnings Scheduled For November 2, 2021
November 02, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
May 06, 2022
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Ultragenyx Pharmaceutical's Earnings Outlook
May 04, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
March 16, 2022
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
March 16, 2022
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to...
Via
Benzinga
Where Ultragenyx Pharmaceutical Stands With Analysts
March 16, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Ultragenyx Pharmaceutical: Q4 Earnings Insights
February 10, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
Ultragenyx Pharmaceutical inc (RARE) Q3 2021 Earnings Call Transcript
November 03, 2021
RARE earnings call for the period ending October 2, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Stocks That Hit 52-Week Lows On Wednesday
January 19, 2022
During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
September 30, 2021
Over the past 3 months, 4 analysts have published their opinion on Ultragenyx Pharmaceutical (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...
Via
Benzinga
Ultragenyx Resumes Dosing Antisense Trial In Rare Neurogenetic Disorder
September 27, 2021
The FDA has removed the clinical hold on GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) GTX-102 trial for...
Via
Benzinga
Exposures
Product Safety
Return on Capital Employed Insights for Ultragenyx Pharmaceutical
August 19, 2021
After pulling data from Benzinga Pro it seems like during Q2, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted sales of $86.97 million. Earnings were up 22.33%, but Ultragenyx...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021
August 19, 2021
Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ:
Via
Benzinga
Return on Capital Employed Overview: Ultragenyx Pharmaceutical
August 13, 2021
After pulling data from Benzinga Pro it seems like during Q2, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted sales of $86.97 million. Earnings were up 22.33%, but Ultragenyx...
Via
Benzinga
Ultragenyx Pharmaceutical inc (RARE) Q2 2021 Earnings Call Transcript
August 03, 2021
RARE earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Ultragenyx Pharmaceutical: Q2 Earnings Insights
August 02, 2021
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down...
Via
Benzinga
Ultragenyx Pharmaceuticals Analyst Turns Bullish: What Investors Need To Know
June 29, 2021
A BofA Securities analyst is turning bullish on shares of Ultragenyx Pharmaceuticals (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021
June 29, 2021
Upgrades For Nutrien Ltd (NYSE:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 29, 2021
Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 42.0% to $17.85 during Tuesday's pre-market session. The company's market cap stands at $2....
Via
Benzinga
Earnings Scheduled For August 2, 2021
August 02, 2021
Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is estimated to report earnings for its second quarter. • Addex Therapeutics (NASDAQ:ADXN) is...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.